CGA and neoplasm: In 2 large clinical trials, monthly administration of somatostatin analogs at anti-proliferative doses specifically, long-acting octreotide 30 milligrams (with significant reduction in CgA) monthly or lanreotide 120 milligrams (without significant improvement of symptoms and biochemical response) every 28 days prolonged the time to tumor progression of metastatic gastrointestinal neuroendocrine tumors (29, 50, 51).